Anti-TNF vs azathioprine after Rutgeerts i3 findings

What is known

• Pooled data suggest anti-TNFs are superior to thiopurines at preventing endoscopic and clinical POR (Rutgeerts ≥i2). ¹
• The APPRECIA randomized trial showed azathioprine had efficacy similar to adalimumab in preventing 1-year endoscopic recurrence; later meta-analyses still ranked anti-TNFs best. ²
• Prospective cohort data show post-operative prophylaxis and anti-TNF specifically reduce 12-month endoscopic and clinical recurrence, but without an i3-stratified anti-TNF vs azathioprine contrast. ^3,4
• In a post-hoc analysis, treating asymptomatic endoscopic recurrence with immunosuppressants/anti-TNF reduced long-term clinical recurrence in i3/i4 but not i2 patients. ⁵

What is unknown / caveats

• APPRECIA RCT: azathioprine non-inferior to adalimumab at 1 year
• Pooled meta-analyses rank anti-TNF above thiopurines
• No retrieved study restricts the anti-TNF vs azathioprine comparison to the Rutgeerts i3 subgroup
• Head-to-head trials used adalimumab, not anti-TNF as a class, in unselected post-op populations
• Whether anti-TNF outperforms azathioprine specifically within the i3 high-risk stratum at 1 year is not directly established by the retrieved evidence.

References

1. Schubach A, Sultan K, Swaminath A. Recurrent Ulceration and Disease at the Ileocolonic Anastomosis in Crohn's Disease: Etiology, Prevention, and Management, a Review Article. J Clin Med. 2025;14(22). PMID: 41303193.

2. Dragoni G, Castiglione F, Bezzio C, Pugliese D, Spagnuolo R, Viola A, Cocomazzi F, Aratari A, Savarino EV, Balestrieri P, Onali S, Viganò C, Ribaldone DG, Innocenti T, Testa A, Saibeni S, Privitera G, Milla M, Armuzzi A, Fantini MC, Fiorino G. Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study. United European Gastroenterol J. 2023;11(3):271-281. PMID: 36942657.

3. Maggiori L, Brouquet A, Zerbib P, Lefevre JH, Denost Q, Germain A, Cotte E, Beyer-Berjot L, Munoz-Bongrand N, Desfourneaux V, Rahili A, Duffas JP, Pautrat K, Denet C, Bridoux V, Meurette G, Faucheron JL, Loriau J, Souche R, Vicaut E, Panis Y, Benoist S, GETAID chirurgie G. Penetrating Crohn Disease Is Not Associated With a Higher Risk of Recurrence After Surgery: A Prospective Nationwide Cohort Conducted by the Getaid Chirurgie Group. Ann Surg. 2019;270(5):827-834. PMID: 31567506.

4. [No authors listed]. Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study. Aliment Pharmacol Ther. 2018;48(9):924-932. PMID: 30126030.

5. Rivière P, Vermeire S, Irles-Depe M, Van Assche G, Rutgeerts P, Denost Q, Wolthuis A, D'Hoore A, Laharie D, Ferrante M. Rates of Postoperative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic Therapies. Clin Gastroenterol Hepatol. 2021;19(4):713-720.e1. PMID: 32272248.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.